Sharescart Research Club logo ×
Screener Research Unlisted Startup Funding New IPO New

Mayur    


Mumbai, India

I have cleared the CFA Level 1 exam and have certification in Financial Modeling & Valuation

Read More..
Contributor since: 2023

29

Articles

27

Likes

4

Followers

Comments: 0 | Likes: 0


PARAGON FINE AND SPECIALITY CHEMICAL LIMITED | INITIAL PUBLIC OFFERNING

Paragon Fine and Speciality Chemicals Limited is a well-established custom synthesis and manufacturing firm specializing in the production of chemical intermediates with a focus on complex and specialized chemistry. The company was founded as a partnership in 2003 and has since transformed into a leading provider of custom synthesis and manufacturing services for a wide range of industries, serving both Indian and international clients. Paragon Limited places a strong emphasis on integrating chemistry with technology and efficient systems to ensure sustainable product development. The company's product portfolio spans various sectors, including pharmaceuticals, agrochemicals, cosmetics, pigments, and dyes, offering a diverse array of chemical intermediates tailored to meet the unique needs of its clients.


PARAGON FINE AND SPECIALITY CHEMICAL LIMITED | INITIAL PUBLIC OFFERNING

On 18th October, 2023 Paragon Fine and Speciality Chemicals Limited officially issued its Prospectus mentioning the important details regarding its recent Initial Public Offering (hereinafter referred as IPO) which had started from Thursday, 26 October, 2023 and will close on Monday, 30 October, 2023. Before delving deeply into the details of the IPO. Let us briefly look at the Business Operation of ‘Paragon Fine and Speciality Chemicals Limited.’

ABOUT BUSINESS OPERATION

Paragon Fine and Speciality Chemicals Limited is a well-established custom synthesis and manufacturing firm specializing in the production of chemical intermediates with a focus on complex and specialized chemistry. The company was founded as a partnership in 2003 and has since transformed into a leading provider of custom synthesis and manufacturing services for a wide range of industries, serving both Indian and international clients. Paragon Limited places a strong emphasis on integrating chemistry with technology and efficient systems to ensure sustainable product development. The company's product portfolio spans various sectors, including pharmaceuticals, agrochemicals, cosmetics, pigments, and dyes, offering a diverse array of chemical intermediates tailored to meet the unique needs of its clients.

Paragon Limited's manufacturing facility, strategically located in the Viramgam District of Ahmedabad, Gujarat, covers approximately 7000 square meters. This state-of-the-art facility is equipped with a variety of reactors capable of producing a wide range of chemical products. Additionally, the company maintains a pilot plant with two glass-lined assembly units and three reactors designed for batch reaction technology. Paragon Limited employs a wide array of chemistry compositions such as Acetylation, Amination, Catalytic Hydrogenation, Chlorosulfonation, Methoxylation, Nitration, Amidation, Ethoxylation, Sulphonation, and more, enabling them to address the intricate and advanced requirements of a broad spectrum of end products and applications. At the heart of Paragon Limited's success lies its dedicated in-house Research and Development (R&D) facility. This facility is fully equipped with laboratories focused on catalytic process development and new chemical screening. The R&D team plays a crucial role in driving innovation and efficiency, from the initial conceptualization of a product to its commercialization. It is worth noting that the Department of Scientific and Industrial Research has recognized the excellence of Paragon Limited's in-house R&D facility. It is the company's robust research and development efforts and technological capabilities, Paragon Limited boasts a diversified product portfolio. Their R&D team has successfully executed multi-step synthesis and scale-up processes for numerous new molecules in the field of specialty intermediates. As a result, the company has expanded its commercialized product range from approximately 100 products in Fiscal 2021 to around 140 products in Fiscal 2023. As of March 31, 2023, Paragon Limited employs a team of 14 technocrats, each holding degrees such as Bachelor of Science, Master of Science, B. Pharma, or Bachelor of Engineering. Paragon Limited holds the distinction of being a One Star Export House, with a strong global presence in countries such as the USA, Israel, Spain, United Kingdom, China, Switzerland, Taiwan, Thailand, Mexico, Japan, Russia, France, Indonesia, Latvia, and Germany. The company's commitment to excellence in custom synthesis and manufacturing, combined with its dedication to cutting-edge research and development, has solidified its position as a trusted and innovative partner in the chemical industry.

PRODUCTS AND SERVICES

Paragon Fine and Speciality Chemicals Limited specializes in the production of six distinct categories of chemical intermediates to cater to various industries.

1. AGRO INTERMEDIATES: The company formulates Agro Intermediates with a strategic focus on enhancing crop protection and boosting agricultural productivity. These tailored formulations are designed to promote the development of safe and effective agrochemicals, ultimately supporting the adoption of sustainable agricultural practices.

2. Pharma Intermediates: Paragon Fine and Speciality Chemicals Limited offers a range of chemical intermediates specifically crafted for the pharmaceutical industry. These intermediates play a crucial role in the synthesis of pharmaceutical products, ensuring the quality and efficacy of medications.

3. Speciality Intermediates: The company provides Speciality Intermediates that are tailored to meet the unique and complex requirements of various industrial applications. These intermediates are developed to enable the production of specialized products with precision and efficiency.

4. Pigment Intermediates: Paragon Fine and Speciality Chemicals Limited Produces Pigment Intermediates designed for the pigment industry. These intermediates serve as essential components in the creation of pigments used in various applications, including paints, coatings, and other colour-related products.

5. Cosmetic Intermediates: The company also manufactures Cosmetic Intermediates, which are instrumental in the formulation of cosmetic and personal care products. These intermediates contribute to the development of safe and effective cosmetic formulations, meeting the high standards of the beauty and personal care industry.

6. Dye Intermediates: Paragon Fine and Speciality Chemicals Limited's Dye Intermediates play a crucial role in the dyeing and colouring industry. These intermediates are engineered to ensure vibrant and lasting coloration in textiles and various other materials.

BOARD OF DIRECTOR AND PROMOTERS OF THE COMPANY

The Board of Directors (BOD) and Promoters of Paragon Fine and Speciality Chemicals Limited comprise a group of key individuals who play pivotal roles in the company's leadership and management. This group includes:

1. Dr. Pravinchandra Jasmat Vasolia is one of the prominent figures on the company's Board of Directors and among its core Promoters. His expertise and insights contribute significantly to the strategic direction and decision-making processes of the organization.

2. Vallabh Ratanji Savaliya is another integral member of the Board of Directors and a key Promoter of the company. His active involvement and leadership within the company have a profound impact on its operations and growth.

3. Kishorkumar Panchabhai Patolia is a distinguished member of the Board of Directors and a Promoter of Paragon Fine and Speciality Chemicals Limited. His contributions and experience play a crucial role in shaping the company's business strategies and initiatives.

4. Rutesh Vallabhbhai Savalia is a significant presence on the Board of Directors and is also listed as a Promoter of the company. His valuable insights and contributions help steer the company toward its goals and objectives.

5. Shivam Kishorbhai Patolia is an essential part of the company's leadership as a member of the Board of Directors and a Promoter. His active participation and expertise contribute to the overall success and growth of Paragon Fine and Speciality Chemicals Limited.

These individuals collectively form the leadership team that guides the company, ensuring that it remains on a path of growth, innovation, and success.

INDUSTRY OUTLOOK

Paragon Fine and Speciality Chemicals Limited is an integral player within the dynamic and evolving Indian chemical industry. This industry has experienced notable shifts, with mostchemicals being de-licensed, except for a select few considered hazardous. Notably, alkali chemicals hold a significant share, accounting for approximately 71.9% of total production in the fiscal year 2022. Moreover, the production of polymers constitutes a substantial portion of the key petrochemical segment, contributing around 59% in 2019.

The Indian chemical industry is a crucial economic contributor, with projections indicating that it will significantly enhance India's GDP by contributing approximately US$ 300 billion by 2025. India holds a strong global position in chemical trade, ranking 14th in exports and 8th in imports (excluding pharmaceuticals). The sector encompasses a vast array of over 80,000 commercial products, with the market size reaching nearly US$ 178 billion in 2018-19. Forecasts suggest robust growth, with the industry expected to expand at a rate of 9.3%, reaching a value of US$ 304 billion by 2025. This growth is largely attributed to increasing demand, especially in the specialty chemicals and petrochemical segments, with the specialty chemicals sector projected to reach a value of US$ 40 billion by 2025.

Furthermore, the agrochemical industry in India depends significantly on the import of raw materials and intermediates, with substantial imports from China. This sector presents an attractive investment opportunity for import substitution and capacity expansion to meet the growing demands of the agricultural sector.

In the pharmaceutical industry, India boasts the world's 3rd largest volume of pharmaceutical production, valued at $50 billion. The country also plays a pivotal role in global pharmaceutical exports, contributing 3.5% of total drugs and medicines shipped to over 200 countries. To bolster domestic production, enhance drug security, and stimulate investment in critical drug categories, the Department of Pharmaceuticals has introduced incentivizing schemes for both global and domestic players. Within this dynamic industry landscape, Paragon Fine and Speciality Chemicals Limited stands as a key player, specializing in the production of chemical intermediates. The company is strategically positioned to leverage the industry's growth and make significant contributions to India's chemical and pharmaceutical sectors, serving a pivotal role in this thriving economic ecosystem.

COMPETITION

Paragon Fine and Speciality Chemicals Limited operates within a highly specialized industry characterized by substantial entry barriers. These barriers encompass several critical factors, such as the need for customer validation and approvals, elevated customer expectations regarding process innovation and cost reduction, stringent quality standards, and exacting product specifications. In this competitive landscape, the company faces diverse rivals whose nature and scale of competition vary across markets, geographic regions, and product types. To maintain a competitive edge in these challenging markets, Paragon Fine and Speciality Chemicals Limited continuously endeavours to optimize its production costs, enhance transportation and distribution efficiencies, and elevate overall operational performance.

Within this niche industry, there are both large and small manufacturers that develop products like those offered by the company. These industry players may possess more substantial financial resources, advanced technology, robust research and development capabilities, extensive market reach, and diversified portfolios of products across various geographic regions. These attributes often enable them to respond more effectively to market dynamics and technological trends.

While Paragon Fine and Speciality Chemicals Limited does not engage in direct competition with any specific listed Indian company that exactly mirrors its range of chemistries, scope of services, and product offerings, it does share some similarities with other listed companies operating in a similar domain. Notable among these industry peers are Aether Industries Limited, Anupam Rasayan India Limited, Bodal Chemicals Limited, and Deepak Nitrite Limited. These companies, like Paragon Fine and Speciality Chemicals Limited, are involved in the production and sale of specialized chemical products, contributing to a competitive landscape that demands continuous innovation, operational excellence, and adaptability to meet the evolving needs of the industry and its diverse customer base.

FINANCIAL ASPECT

When considering an investment in a company, investors invariably scrutinize the Key Financial Indicators to make informed decisions. Among these, Revenue from Operationsstands out as a pivotal figure. Notably, in the Financial Year 2022-23, Paragon Fine and Speciality Chemicals Limited has generated a remarkable revenue of INR 10226.62 (inLakhs). And in the FY 2021-22 it had a revenue of INR 8282.94 (in Lakhs). Their profit for the FY 2022-23 stands at INR 989.21 (in Lakhs). And the profit for the FY 2021-22 stands at INR 449.02 (in Lakhs).

Paragon Fine and Speciality Chemicals Limited's financial performance for the fiscal year 2022-23 exhibited significant growth. The total income for this period reached Rs. 10,501.19 Lakhs, reflecting a notable increase of 24.16% compared to the previous fiscal year 2021-22when it stood at Rs. 8,457.92 Lakhs. This remarkable expansion in total income was primarily attributed to the company's expanded business operations within the domestic market. The total income encompasses both revenue from operations and other income. Specifically, the net revenue from operations for the fiscal year 2022-23 witnessed a substantial increase, reaching Rs. 10,226.62 Lakhs. This represents a growth of 23.47% in comparison to the Rs. 8,282.94 Lakhs achieved in the financial year 2021-22. The primary drivers for this increase were elevated sales in several key segments:

1. Cosmetics Intermediates: Sales increased from Rs. 590.15 Lakhs in FY 2021-22 to Rs. 630.07 Lakhs in FY 2022-23, marking a growth of 6.76%.

2. Dyes Intermediates: Sales surged from Rs. 5,187.98 Lakhs in FY 2021-22 to Rs. 7,044.37 Lakhs in FY 2022-23, indicating an impressive growth of 35.78%.

3. Pharma Intermediates: Sales grew from Rs. 6.31 Lakhs in FY 2021-22 to Rs. 6.66 Lakhs in FY 2022-23, reflecting an increase of 5.55%.

However, along with increased revenue, total expenses for the fiscal year 2022-23 also rose to Rs. 9,144.67 Lakhs from Rs. 7,840.85 Lakhs in the previous fiscal year, marking a 16.63% increase. This expense growth was directly linked to the company's expanded business activities.

As a result of these financial developments, the profit after tax (PAT) experienced substantial growth, surging by 120.30% from a net profit of Rs. 449.02 Lakhs in the financial year 2021-22 to an impressive net profit of Rs. 989.21 Lakhs in the financial year 2022-23. Consequently, the PAT Margin also expanded, reaching 9.67% in the fiscal year 2022-23, compared to 5.42% in the fiscal year 2021-22. These financial achievements underscore the company's robust performance and its ability to effectively capitalize on business opportunities, driving both revenue growth and profitability. For a more comprehensive understanding of the financial aspects of Paragon Fine and Speciality Chemicals Limited, the following table provides valuable insights of financial ratios for a comprehensive assessment of the company's financial condition and performance.

RATIO NAME

FY 2022-23

FY 2021-22

RETURN ON EQUITY

56.89%

44.03%

RETURN ON CAPITALEMPLOYED

38.86%

24.90%

NET PROFIT

9.67%

5.42%

 

OBJECTIVE OF THE IPO

The company's decision to go public and list its Equity Shares on the NSE Emerge (SME Platform) is driven by several strategic objectives aimed at enhancing its corporate image, brand visibility, and shareholder value. Other than this the company's intentions behind the initial public offering (IPO) are as follows:

1. Funding Capital Expenditure: The IPO will serve as a source of funds to support critical capital expenditure requirements. Specifically, it will be directed towards civil construction work within the existing factory premises, enhancing infrastructure and operational capabilities.

2. Debt Repayment: Part of the proceeds from the IPO will be allocated for the complete or partial repayment of existing borrowings. This move will contribute to optimizing the company's financial structure and reducing interest expenses, ultimately strengthening its financial position.

3. Expansion Initiatives Paragon Fine and Speciality Chemicals Limited intends to utilize IPO funds for the acquisition and installation of additional plant and machinery. This investment in expansion aims to increase production capacity and operational efficiency to meet growing market demands.

4. Working Capital Needs: A portion of the IPO proceeds will be earmarked to support working capital requirements. Adequate working capital is crucial for smooth day-to-day operations, ensuring that the company can meet its obligations and seize business opportunities.

5. General Corporate Purpose: The IPO will also provide a pool of capital for general corporate purposes, which may encompass a wide range of initiatives aimed at strengthening the company's overall operations, research and development, and strategic growth.

IMPORTANT DATES

EVENTS

DATES

Bid/Issue Opening

Thursday, October 26, 2023

Bid/Issue Closing

Monday, October 30, 2023

Finalization of Basis of Allotment with the Designated Stock Exchange

On or about Thursday, November 02, 2023

Initiation of Allotment / Refunds / Unblocking of Funds from ASBA Account or UPI ID linked bank account

On or about Friday, November 03, 2023

Credit of Equity Shares to Demat accounts of Allottees

On or about Monday, November 06, 2023

Commencement of trading of the Equity Shares on the Stock Exchange

On or about Tuesday, November 07, 2023

DETAILS OF THE IPO

The current Public Issue offered by Paragon Fine and Speciality Chemicals Limited involves the issuance of up to 51,66,000 Equity Shares, duly authorized by the company's Board of Directors. Each Equity Share has a face value of ₹10. The Issue Price has been set with a Price Band, ranging from ₹95 per Equity Share at the lower end ("Floor Price") to ₹100 per Equity Share at the higher end ("Cap Price"). Allotment of Equity Shares through this Issue will be carried out in multiples of 1200 Equity Shares.

The structure of the Issue consists of two key components:

1. Market Maker Reservation Portion: This segment involves the reservation of up to 2,61,600 Equity Shares, each with a face value of ₹10, exclusively for subscription by the designated Market Maker.

2. Net Issue to Public: The remaining portion of the Issue comprises up to 49,04,400 Equity Shares, also with a face value of ₹10 each. These Equity Shares are made available for subscription by the public.

The combined effect of the Issue and the Net Issue will result in a total of 26.40% and 25.07% of the post-Issue paid-up equity share capital of Paragon Fine and Speciality Chemicals Limited, respectively. These allocations represent the distribution of shares to various categories of investors as follows:

 

Qualified Institutional Buyers (QIBs): The number of equities shares available for allocation to QIBs is not more than 24,51,600 Equity Shares.
Non-Individual Investors: A Subscription of 7,35,600 Equity Shares is set as the limit for allocation to non-individual investors.
Retail Individual Investors: A total of 17,17,200 Equity Shares are available for allocation to retail individual investors.

This well-structured allocation approach aims to accommodate a diverse range of investors, ensuring equitable access to Paragon Fine and Speciality Chemicals Limited's Equity Shares during this Public Issue.

RISKS INVOLVED

The operational sustainability of Paragon Fine and Speciality Chemicals Limited is intricately linked to several critical factors, and the company is exposed to various risks that could potentially impact its business:

1. Dependence on R&D Capabilities: The company's capacity to design complex chemistries is essential for its competitive edge. This relies on successful technology development, the recruitment and training of qualified personnel, production processes, market trend identification, and demand for new products. The inability to secure necessary technological knowledge through R&D or respond to industry trends could affect the product portfolio.
2. Manufacturing Risks: The company's operations heavily rely on manufacturing facilities, and any slowdown, shutdown, strikes, work stoppages, or increased wage demands by employees could disrupt operations, potentially adversely affecting the company's financial condition and results.
3. Hazardous Substances Handling: The manufacturing processes involve the use, storage, and transportation of hazardous substances. These substances require approvals from relevant authorities. However, handling such materials poses inherent risks, including leakages, container ruptures, explosions, and the release of toxic substances. These risks could lead to personal injury, property damage, and environmental contamination, potentially causing interruptions in business operations.
4. Customer Concentration Risk: Paragon Fine and Speciality Chemicals Limited derives a significant portion of its revenue from major customers and lacks long-term contracts with all of them. A decision by one or more major customers to discontinue sourcing or terminate contracts could adversely affect the company's financial position.
5. Industry Dependence: The company's revenue is closely tied to the industries that use its products as inputs, such as Pharma, Agrochemicals, Cosmetics, Textile, specialty pigments and dyes, additives, and polymers. The absence of patents for its processes and potential challenges to trademark applications could result in insufficient protection for intellectual property rights, potentially impacting the business.
6. International Trade Risk: The company significantly depends on international trade, historically generating a substantial portion of its revenues from exports to countries including the USA, Israel, Spain, the United Kingdom, China, Switzerland, Taiwan, the Netherlands, Thailand, Mexico, Japan, Russia, France, Indonesia, Latvia, and Germany. This exposes the company to risks associated with global trade dynamics, including economic and geopolitical uncertainties that can affect its international business operations.

 

Disclosure:

I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.

Business relationship disclosure:

I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Stocx Research Club). I have no business relationship with any company whose stock is mentioned in this article.

Disclosure legality:

I am not a SEBI Registered individual/entity and the above research article is only for educational purpose and is never intended as trading/investment advice.

Articles

Updated : May, 2024

Market Watch: Forecasting Post-Election Market Trend...

As voters prepare to cast their votes, market analysts often look for clues as to how the outcome of the general election, which will determine India's leadership for the next five years, might effect public opinion. elections are most crucial part for...

Author : Nikhil Singh

Updated : May, 2024

NSE's Q4 Result Analysis : Strong Results along with...

The National Stock Exchange (NSE) has recently announced its financial results for Q4 of the fiscal year 2024, showcasing strong growth across various financial metrics. The consolidated revenue from operations surged by an impressive 34% year-on-year,...

Author : Sudarshan

Updated : May, 2024

Nifty surged to almost life time high on bank earnin...

Bank Nifty also scaled life time high; looking ahead, Dalal Street's trajectory may depend on India's election trajectory

Author : Ashish Ghosh

Updated : Apr, 2024

Nifty may come under stress on growing election unce...

Dow and Nifty Future recovered on Friday as Iran downplayed the Israel retaliation; India may be heading for a hung Parliament as BJP may not get over 250 seats alone

Author : Ashish Ghosh

Updated : Apr, 2024

The Rise of Digit Insurance and Its Journey

Mr. Kamesh Goyal founded Digit Auto Insurance in 2016. The company, Digit Insurance, focuses on streamlining insurance procedures and providing quick claim settlements. It is India's first digital general insurance provider.

Author : Nikhil Singh

Updated : Apr, 2024

Nifty gained almost 30% in FY24 on positive global c...

Depending on likely poll outcome and various scenarios, Nifty may scale 23500-24500 by FY25, while may also correct to 20300-19500 (if BJP fails to get min 273 seats alone)

Author : Ashish Ghosh

Updated : May, 2024

NSE's Q4 Result Analysis : Strong Results along with...

The National Stock Exchange (NSE) has recently announced its financial results for Q4 of the fiscal year 2024, showcasing strong growth across various financial metrics. The consolidated revenue from operations surged by an impressive 34% year-on-year,...

Author : Sudarshan

Updated : Feb, 2024

IPO Analysis: Capital Small Finance Bank Ltd.

IPO analysis of Capital Small Finance Bank Ltd.

Author : Shalom Martin

Updated : Feb, 2024

Payment Revolution: A Deep Dive into Razorpay's Ecos...

Razorpay, a leading player in the payment solutions sector, has established itself as a formidable force, securing the 3rd rank among 384 competitors. The company operates in a vibrant landscape, with 317 active competitors, of which 48 have received f...

Author : Nikhil Singh

Updated : Feb, 2024

CAPITAL SMALL FINANCE BANK LIMITED - IPO Analysis

The ‘Capital Small Finance Bank Limited’ officially issued its Prospectus on February 01, 2024 mentioning the important details regarding its recent Initial Public Offering (hereinafter referred as IPO) which has started from February 07, 2024 and ...

Author : Vijay Sankhala

Updated : Feb, 2024

CultFit IPO Unveiled: From Business Model to Valuati...

Cult.fit, founded in 2015 by Mukesh Bansal and Ankit Nagori, has emerged as a prominent health and fitness platform. Offering diverse fitness modules both offline and online, including strength training, yoga, and dance fitness, Cult.fit has garnered i...

Author : Nikhil Singh

Updated : Feb, 2024

MobiKwik's Financial Frontier: A Comprehensive IPO P...

The article focuses on MobiKwik's success in the digital payments industry, emphasising its early acceptance and flexibility to shifting online payment patterns. It implies that MobiKwik's proactive expansion and the expected rise in virtual platforms ...

Author : Nikhil Singh

Updated : Jun, 2022

Equity Research Report: Sakar Healthcare

Sakar Healthcare Ltd is engaged in manufacturing of pharmaceutical formulations in the form of liquid injectables, tablets/ capsules, oral liquid syrups, dry powder injectables and syrups. Presently, its domestic sales accounts for 31% of revenues and ...

Author : Akshita

Updated : Jun, 2022

EQUITY RESEARCH REPORT: NEWGEN SOFTWARE

Newgen Software Technologies is a global software Company and is engaged in the business of software product development including designing and delivering end-to-end software solutions covering the entire spectrum of software services from workflow au...

Author : Akshita

Updated : Jun, 2022

Nifty and Bank Nifty Tumbles Due to Weak Global Cues...

Nifty and Bank Nifty tumbles due to weak global cues lead by higher inflation data, higher crude oil prices and weakening currency.

Author : Shalom Martin

Updated : Jun, 2022

Equity Research Report: Shree Renuka Sugar

Shree Renuka Sugars is a global agribusiness and bio-energy corporation. The Company is one of the largest sugar producers in the world, the leading manufacturer of sugar in India, and one of the largest sugar refineries in the world.

Author : Akshita

Updated : Jul, 2022

Equity Research : Tata Consumer Products Limited

TCPL future ambitions remain aggressive, At 17% EPS CAGR over FY22-25e, TCPL should deliver industry-leading growth within indian FMCG.

Author : Shalom Martin

Updated : Jul, 2022

Equity Research: Birlasoft Ltd

Birlasoft, a small-cap IT company, has an upside potential of 35%. The company’s repeated demonstration of ‘walking the talk’ makes us believe that it is on track to achieve its stated target of USD1bn revenue by FY25E.

Author : Shalom Martin

Comments

IPO

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....

Companies Open Date Close Date Issue Price Cost of 1 Lot GMP Expected Listing Listing Gain(%) Listing Price Current Price Type Exchange

View more.....